Disease modifying Antirheumatic Drugs
Drugs acting on colon and rectum
Psoriasis, seborrhea and ichthyosis
= Additional active ingredients
Adalimumab 40 mg/0.80 ml.
PRESENTATION AND DOSSAGE
PREFILLED PEN (sol. for injec.) X 2
PREFILLED SYRINGE (solution for injection): 2 (with needle guard).
VIAL (solution for injection): 2 (with vial adapter).
Adalimumab has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis patients taking Adalimumab as monotherapy and those taking concomitant methotrexate. Antibody formation was lower when Adalimumab was given together with methotrexate in comparison with use as monotherapy. Administration of Adalimumab without methotrexate resulted in increased formation of antibodies, increased clearance and reduced efficacy of adalimumab . The combination of Adalimumab and anakinra is not recommended. The combination of Adalimumab and abatacept is not recommended.
See prescribing information for full details.
Hypersensitivity to the active substance or to any of the excipients. Active tuberculosis or other severe infections such as sepsis, and opportunistic infections. Moderate to severe heart failure (NYHA class III/IV).
Decreased hemoglobin. Hyperlipidemia, headache, dizziness. Upper respiratory infection, rhinitis, sinusitis, bronchitis, increased cough, pneumonia, nausea, diarrhea, sore throat. Dehydration, rash, pruritis, herpes simplex, UTI, abnormal laboratory tests, asthenia, clinical flare reaction, flu syndrome, abdominal pain, infection. Injection site pain reaction, hemorrhage, and eruption. See prescribing information for full details.
In the absence of compatibility studies, this product must not be mixed with other medicdbinal products.
MANUFACTURER & DISTRIBUTER:
Manufacturer: Abbott medicdbal Laboratories
License Holder: AbbVie biopharmaceuticals Ltd., Israel